Table 2.
Seropositivity of patients with different severity of disease regarding aIFN-1 and its subtypes AAbs.
| First author | Sample size | aIFN-l- Circulating/Neutralizing | Circulating aIFN-α2/ω/β |
Neutralizing activity against aIFN-α2/ω/β |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Critical | Severe | Moderate | Mild | Critical | Severe | Moderate | Mild | |||
| Goncalves et al. | 94 | −/− | 21 of 84/10 of 21*/1 of 21* | −/−/- | −/−/- | 0 of 10/−/− | 15 of 84/10 of 21*/1 of 21* | −/−/- | −/−/- | 0 of 10/−/− |
| Van der Wijst et al. | 284 | −/− | 5 of 26/−/− | 6 of 102/−/− | 0 of 156/−/− | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- |
| Solanich et al. | 275 | 49/26 | −/−/- | 41 of 275/30 of 275/- | −/−/- | −/−/- | −/−/- | 25 of 275/22 of 275/- | −/−/- | −/−/- |
| Chauvineau-Grenier et al. | 139 | −/− | −/−/- | 9 of 139/-/0 of 86 | −/−/- | −/−/- | −/−/- | 6 of 139/-/0 of 86 | −/−/- | −/−/- |
| Busnadiego et al. | 103 | 12/- | 12 of 103/8 of 103/0 of 103 | −/−/- | −/−/- | −/−/- | 11 of 103/-/0 of 103 | −/−/- | −/−/- | −/−/- |
| Bastard et al. (Duplicate) | 1650 | −/− | −/−/- | −/−/- | −/−/- | 0 of 663/0 of 663/- | 88 of 987/65 of 987/- | −/−/- | −/−/- | 0 of 663/0 of 663/- |
| Bastard et al. | 4117 | -/523 | −/−/- | −/−/- | −/−/- | −/−/- | 360 of 3595/385 of 3595/23 of 1773 | 32 of 522/20 of 522/0 of 187 | −/−/- | 5 of 1639/13 of 1639/- |
| Akbil et al. | 403 | 28/- | 20 of 403/17 of 403/- | 18 of 237/11 of 237/- | −/−/- | −/−/- | −/−/- | |||
| Abers et al. | 44 | 2/2 | −/−/- | −/−/- | −/−/- | −/−/- | −/−/1 of 135 | 0 of 44/2 of 44/- | −/−/- | −/−/- |
| Troya et al. | 47 | 5/5 | −/−/- | −/−/- | −/−/- | −/−/- | 3 of 16/3 of 16/- | 2 of 31/2 of 31/- | −/−/- | −/−/- |
| Frasca et al. | 360 | 61/- | −/−/- | −/−/- | −/−/- | −/−/- | 13 of 360/9 of 360/37 of 360 | |||
| Lopez et al. | 56 | −/− | 10 of 56/−/− | −/−/- | −/−/- | −/−/- | −/−/- | |||
| Troya et al. | 178 | −/− | −/−/- | −/−/- | −/−/- | −/−/- | 27 of 178/26 of 178/1 of 178 | −/−/- | −/−/- | −/−/- |
| Koning et al. | 210 | 35/6 | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- |
| Eto et al. | 622 | -/26 | 8 of 170/6 of 170/- | 2 of 235/2 of 235/- | 1 of 112/0 of 112/- | 1 of 105/3 of 105/- | 12 of 170/17 of 170/- | 6 of 235/3 of 235/- | 1 of 112/1 of 112/- | 1 of 105/0 of 105/- |
| Raadsen et al. | 282 | −/− | 5 of 38/−/− | 7 of 97/−/− | 0 of 43/−/− | 4 of 100/−/− | 5 of 38/−/− | 7 of 97/−/− | 0 of 43/−/− | 1 of 100/−/− |
| Chang et al. | 48 | 23/- | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- |
| Wang et al. | 194 | 52/- | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- |
| Vazquez et al. | 116 | −/− | 4 of 116/−/− | 2 of 116/−/− | ||||||
| Manry et al. | 1121 | 305/- | −/−/- | −/−/- | −/−/- | −/−/- | 140 of 1121/165 of 1121/6 of 1094 | −/−/- | −/−/- | −/−/- |
| Savvateeva et al. | 86 | 10/- | 7 of 86/6 of 86/- | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- |
| Yee et al. | 127 | -/4 | −/−/- | −/−/- | −/−/- | −/−/- | 4 of 103 (IFN-α or IFN-ω) | 0 of 24 (IFN-α or IFN-ω) | ||
| Steels et al. | 52 | −/− | −/−/- | 8 of 52/−/− | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- |
| Ziegler et al. | 20 | −/− | −/−/- | 1 of 8/1 of 8/- | 0 of 12/0 of 12/- | −/−/- | −/−/- | −/−/- | −/−/- | |
| Soltani-Zangbar et al. | 100 | −/− | −/−/- | 14 of 50/−/− | −/−/- | 2 of 50/−/− | −/−/- | −/−/- | −/−/- | −/−/- |
| Scordio et al. | 8 | −/− | −/−/- | −/−/- | −/−/- | −/−/- | 2 of 3/2 of 3/- | −/−/- | 1 of 3/2 of 3/- | 0 of 2/1 of 2/- |
| Mathian et al. | 5 | −/− | −/−/- | −/−/- | −/−/- | −/−/- | 4 of 5/4 of 5/2 of 5 | −/−/- | −/−/- | |
| Smith et al. | 126 | −/− | −/−/- | −/−/- | −/−/- | −/−/- | 4 of 126/−/− | |||
| Arrestier et al. | 925 | -/96 | −/−/- | −/−/- | −/−/- | −/−/- | 74 of 925/71 of 925/12 of 925 | −/−/- | −/−/- | −/−/- |
| Bodansky et al. | 213 | −/− | −/−/- | 1 of 168/−/− | −/−/- | 0 of 45/−/− | −/−/- | −/−/- | −/−/- | −/−/- |
| Matuozzo et al. (Duplicate) | 928 | 234/- | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- |
| Acosta-Ampudia et al. | 18 | −/− | −/−/- | 3 of 18/−/− | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- |
| Carapito et al. | 72 | 2/- | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- | −/−/- |
| Total | 13023 | 818/688 | 12.2 % [7.0, 20.4]/4.9 % [2.8, 8.5]/0 % | 8.4 % [4.8, 14.3]/5.0 % [0.8, 24.7]/0 % | 0.7 % [0.2, 2.9]/0 %/- | 2.5 % [1.3, 4.8]/1.7 % [0.6, 4.7]/- | 10.6 % [8.7, 12.8]/10.8 % [8.4, 13.9]/1.1 % [0.8, 1.5] | 6.3 % [5.1, 7.8]/4.4 % [2.4, 7.9]/0 % | 3.5 % [0.3, 32.8]/11.4 % [0.1, 96.2]/- | 1.2 % [0.3, 4.7]/2.8 % [0.2, 32.5]/- |
aIFN: Anti-Interferon*Among patients who were positive for aIFN-α2.